Canacords's analyst commentsFrom Canaccord’s morning coffeehouse today: Quipt Home Medical Corp.* (QIPT: $6.31), Net Change: -$0.04, Change: -0.63% Unremarkable end to F2022 but several tailwinds on the horizon • On Wednesday night, Quipt Home Medical Corp. press released the highlights of its FQ4/22 financial results (quarter ending September 30) • Revenue of $40.1M (+38% Y/Y) came in slightly behind consensus of $40.4M, where during the quarter, QIPT set up or delivered 145,646 pieces of equipment (+34% Y/Y), including 66,830 respiratory resupplies (+43% Y/Y) • On a sequential basis, QIPT noted that organic growth was nil, below the company's usual 7-10% Y/Y and the broader industry's 4-5% Y/Y growth, primarily due to the cascading negative impact of lower sleep device set-ups this year • On a positive note, QIPT believes this was the trough and expects organic growth to inflect back up to, at minimum, its historic growth levels in F2023